Anticancer research
-
Anticancer research · May 2011
Comparative StudyBevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer. However, clinical data for capecitabine and irinotecan (XELIRI) with bevacizumab are limited. ⋯ Bevacizumab is similarly efficacious and well tolerated when administered with XELIRI or FOLFIRI.